Evaluation of supplementation of garden cress seeds on expressed breast milk volumes in postpartum subjects
Phase 2
- Conditions
- Health Condition 1: O924- Hypogalactia
- Registration Number
- CTRI/2020/11/029185
- Lead Sponsor
- Prathima Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
women who had delivered infants <32 weeks gestation.
Exclusion Criteria
the women could not breastfeed because of her clinical condition.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method difference in milk production at 28 days with administration of study drug compared to placebo groupTimepoint: 28 days
- Secondary Outcome Measures
Name Time Method Secondary end points were occurrence of any side effects with the use of study drugTimepoint: 28 dAYS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does garden cress seed supplementation target to increase breast milk volume in hypogalactia?
How does garden cress seed efficacy compare to standard galactogogues like fenugreek or domperidone in postpartum lactation support?
Are there specific biomarkers (e.g., prolactin, oxytocin) that predict response to garden cress seed supplementation in hypogalactia patients?
What adverse events are associated with garden cress seed use in postpartum women, and how do they compare to herbal galactogogues?
What combination therapies or alternative botanicals synergize with garden cress seeds for hypogalactia treatment in phase II trials?